Medtronic, Watson app to aide diabetes management

Sugar.IQ, a new app from Medtronic that uses IBM Watson computing power, is enrolling its first users, according to a company press release.

The app uses real-time data from continuous glucose monitors and insulin pumps to find patterns and then offer personalized insights to the user.

Sugar.IQ can be used to answer questions about the user’s current health status and how it could improve. It also offers notifications about how specific action and habits affect glucose. Users can also track their activities and food to understand patterns with their glucose levels.

“Through our collaboration with IBM Watson Health, Medtronic will arm people with diabetes with a unique solution that could uncover previously unknown patterns while serving as a personal assistant that offers meaningful information when it matters to help transform diabetes care for greater freedom and better health.” Annette Brüls, president of diabetes service and solutions at Medtronic, said in the release.

Medtronic is currently enrolling 100 early test users, but once available, it will be offered to those who use Medtronic’s devices.

This release coincides with the recent FDA approval of Medtronic’s hybrid closed loop insulin delivery system.

Disclosure: Brüls reports no relevant financial disclosures.

Sugar.IQ, a new app from Medtronic that uses IBM Watson computing power, is enrolling its first users, according to a company press release.

The app uses real-time data from continuous glucose monitors and insulin pumps to find patterns and then offer personalized insights to the user.

Sugar.IQ can be used to answer questions about the user’s current health status and how it could improve. It also offers notifications about how specific action and habits affect glucose. Users can also track their activities and food to understand patterns with their glucose levels.

“Through our collaboration with IBM Watson Health, Medtronic will arm people with diabetes with a unique solution that could uncover previously unknown patterns while serving as a personal assistant that offers meaningful information when it matters to help transform diabetes care for greater freedom and better health.” Annette Brüls, president of diabetes service and solutions at Medtronic, said in the release.

Medtronic is currently enrolling 100 early test users, but once available, it will be offered to those who use Medtronic’s devices.

This release coincides with the recent FDA approval of Medtronic’s hybrid closed loop insulin delivery system.

Disclosure: Brüls reports no relevant financial disclosures.